Accessibility: Skip TopNav
1002-039 Phase 2 Add-on to PCSK9i – Safety & Tolerability
Overview of Adverse Events and Discontinuations
Format
PNG
Source
Esperion Therapeutics, Inc.
Downloads
Original
Large
Medium
Small